Company Overview and News
KUALA LUMPUR (Aug 7): The FBM KLCI rose 0.43% at the midday break today as index-linked blue chip stocks lifted the local benchmark index.
HLFBF 7062 7052 7060 7036 1082 5681 BATS 4162 5014 6033 4634 1783 5029 PNADF 5347 5016 1589 SGPBY TNABY 2739 MYPRY TNABF PNAGF
KUALA LUMPUR (July 30): The FBM KLCI remained subdued at the midday break today, tracking its regional peers.
HLFBF APEXF 7090 8621 7036 BATS 4162 5014 5029 3026 5225 3867 1589 2739 IHHHF PNAGF 1082 5681 6033 5139 PNADF 0900 MYPRY Q0F 3719
KUALA LUMPUR (July 24): The FBM KLCI gained 0.29% at midday break today, tracking the uptrend at most Asian markets, lifted by select index-linked blue chips.
UPBMF 4065 5681 2089 6033 3204 PNADF 3301 7986 3867 1589 5819 0118 PNAGF 1929
KUALA LUMPUR (July 23): Iskandar Waterfront City Bhd (IWCity) fell 6.17% in active trade this morning after the company announced that its parent firm, Iskandar Waterfront Holdings Sdn Bhd (IWH), has not submitted a fresh bid for projects related to the development of Bandar Malaysia, whose gross devlopment value was previously estimated to be RM160 billion.
KUALA LUMPUR (July 20): Based on corporate announcements and news flow, companies that may be in focus on Monday (July 23) include the following: Gamuda Bhd, Iskandar Waterfront City Bhd, BIMB Holdings Bhd, Salcon Bhd, Cabnet Holdings Bhd, Sunway Construction Group Bhd, Sunway Real Estate Investment Trust and Media Chinese International Ltd. Gamuda Bhd’s 40% associate Syarikat Pengeluar Air Selangor Holdings Sdn Bhd (Splash) has withdrawn its claims against Syarikat Bekalan Air Selangor Sdn Bhd (Syabas) in order to facilitate negotiations on the disposal of Splash with the State government of Selangor.
5090 5258 1589 5176 5263
KUALA LUMPUR (July 20): Iskandar Waterfront City Bhd (IWCity) announced that its parent firm, Iskandar Waterfront Holdings Sdn Bhd (IWH), has not submitted a fresh bid for projects related to the development of Bandar Malaysia, which was earlier touted to be worth RM160 billion in gross development value.
1589 BSMAF 1818
KUALA LUMPUR: Iskandar Waterfront City Bhd (IWCity) says parent company Iskandar Waterfront Holdings Sdn Bhd (IWH) has not made any fresh attempt to bid for the development of Bandar Malaysia.
KUALA LUMPUR, July 20 — Bursa Malaysia snapped a nine-day winning streak to close easier today on technical correction, amid a recovery in the Chinese market and overnight Wall Street decline, said a dealer.
7172 PBLOF 1589 1295 BSMAF 1818
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...